PharmiWeb.com - Global Pharma News & Resources
28-Mar-2019

Macular Degeneration Treatment Market Is Expected To Reach Approximately Us$ 11.4 Billion By 2026 | CAGR: 6.6%

According to a new market research report "Macular Degeneration Treatment Market (By Disease Indication: Dry Age-related Macular Degeneration Treatment, Wet Age-related Macular Degeneration Treatment, Others; By Drug Class: Anti-vascular endothelial growth factor, Others; By End-user: Ambulatory Surgical Centers, Hospitals, Ophthalmic Clinics) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026" published by Acumen Research and Consulting, the global macular degeneration treatment market size is anticipated to value USD 11.4 billion by 2026, this market is anticipated to grow with 6.6% CAGR during the forecast time period. Increase in age-related macular degeneration treatment (AMD) is expected to drive the growth of the global macular degeneration treatment market.

Rise in Ramp;D investments by manufacturers leads to innovation of products that used for treatment of macular degeneration diseases. Upsurge in incidence of retinal disorders, and rise in elderly population across developed economies are the factors that are expected to boost the growth of global macular degeneration treatment market during the forecast period. The continuous pressure from other key players in mandating the usage of different drugs for wet AMD and intrusive administration methods are expected to hamper the global macular degeneration treatment market in the upcoming years. However, the countries in developing economies such as U.S, Australia, Japan, Canada, France and others Australia are offering huge opportunities to the manufacturers in the global macular degeneration treatment market. This is driven by huge number of patient population, improved healthcare infrastructure, rising demand of anti-VEGF drugs.

Request a Sample Copy of this Research Report:https://www.acumenresearchandconsulting.com/request-sample/1203

Proliferation of drugs used for the treatment of AMD is projected to drive the growth of the age-related macular degeneration market, also for the treatment of wet AMD, there is no FDA approved treatment. Surge in demand of drugs for AMD treatment is another major driver of the age-related macular degeneration market. The cost of healthcare is increasing in hospitals and clinics which is expected to create concern amongst patients. The treatment cost is high due to the usage of advanced technologies and innovative drugs, rising cost of medicines, high administrative cost, and doctor fees. Additionally, the rise in treatment cost leads to the increase in healthcare spending.

The increase in off-label use and lack of awareness regarding AMD are the restraining factors that is expected to hinder the growth of age-related macular degeneration market. Off-label is the process of utilizing medicines for different medical condition, and different dosing that is not printed on the packing label of the medicines. The vision doctor or ophthalmologists are using doses of Avastin that is used for AMD treatment is highly expensive and unsafe as compared to anti-VEGF drug.

The global macular degeneration treatment market is segmented into disease indication, drug class, distribution channel, and region. On the basis of disease indication, the global macular degeneration treatment market is segmented into dry age-related macular degeneration treatment, wet age-related macular degeneration treatment, and others. On the basis of drug class, the global macular degeneration treatment market is segmented into anti-vascular endothelial growth factor (anti-VEGF) and others. On the basis of distribution channel, the global macular degeneration treatment market is segmented into ambulatory surgical centers, ophthalmic clinics, and hospitals. On the basis of region the global macular degeneration treatment market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East amp; Africa.

Browse Full Report with Table of Content, List of Table and Figures@https://www.acumenresearchandconsulting.com/macular-degeneration-treatment-market

North America region is anticipated to dominate the global macular degeneration treatment market followed by Europe and Asia Pacific region. The market in emerging economies is expected to lose share to high growth economies of Asia Pacific. Extensive adoption of drugs for dry age-related macular degeneration treatments may be attributed to high penetration in the North America region. The hospital segment is expected to grow remarkably due to the increasing preference of patient to visit hospitals as compared to ophthalmic clinics. These factor can boost the growth of macular degeneration treatment in end user segment over the coming years.

Some of the prominent vendors operating in the global macular degeneration treatment market are GlaxoSmithKline plc, Novartis AG, Bayer AG, Neurotech Pharmaceuticals, Inc., Ophthotech Corporation, F. Hoffmann-La Roche Ltd., StemCells Inc., Pfizer, Inc., Sanofi, Santen Pharmaceuticals, Allergan, Inc., and Valeant Pharmaceuticals etc. The macular degeneration treatment market is characterized by a large number of partnership and acquisitions, rise in number of product launch and growing dominance of the prominent players. Increase in investments by vendors on research and development activities coupled with technological advancements to offer advanced solutions are predicted to create incremental growth opportunities for industry players in the global macular degeneration treatment market.

Browse More Press Releases, Click Here:https://www.acumenresearchandconsulting.com/press-releases

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Macular Degeneration Treatment
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Macular Degeneration Treatment Market By Disease Indication
1.2.2.1. Global Macular Degeneration Treatment Market Revenue and Growth Rate Comparison By Disease Indication (2015-2026)
1.2.2.2. Global Macular Degeneration Treatment Market Revenue Share By Disease Indication in 2017
1.2.2.3. Dry Age-related Macular Degeneration Treatment
1.2.2.4. Wet Age-related Macular Degeneration Treatment
1.2.2.5. Others
1.2.3. Macular Degeneration Treatment Market By Drug Class
1.2.3.1. Global Macular Degeneration Treatment Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
1.2.3.2. Anti-vascular endothelial growth factor
1.2.3.3. Others
1.2.4. Macular Degeneration Treatment Market By End Users
1.2.4.1. Global Macular Degeneration Treatment Market Revenue and Growth Rate Comparison By End Users (2015-2026)
1.2.4.2. Ambulatory Surgical Centers
1.2.4.3. Hospitals
1.2.4.4. Ophthalmic Clinics
1.2.5. Macular Degeneration Treatment Market by Geography
1.2.5.1. Global Macular Degeneration Treatment Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Macular Degeneration Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Macular Degeneration Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Macular Degeneration Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Macular Degeneration Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Macular Degeneration Treatment Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Hospitals Production Date of Global Macular Degeneration Treatment Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Macular Degeneration Treatment Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Source of Global Macular Degeneration Treatment Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Macular Degeneration Treatment Major Manufacturers in 2017

CHAPTER 4. MACULAR DEGENERATION TREATMENT MARKET BY DISEASE INDICATION

4.1. Global Macular Degeneration Treatment Revenue By Disease Indication
4.2. Dry Age-related Macular Degeneration Treatment
4.2.1. Market Revenue and Growth Rate, 2015 ndash; 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 ndash; 2026 ($Million)
4.3. Wet Age-related Macular Degeneration Treatment
4.3.1. Market Revenue and Growth Rate, 2015 ndash; 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 ndash; 2026 ($Million)
4.4. Others
4.4.1. Market Revenue and Growth Rate, 2015 ndash; 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 ndash; 2026 ($Million)

CHAPTER 5. MACULAR DEGENERATION TREATMENT MARKET BY DRUG CLASS

5.1. Global Macular Degeneration Treatment Revenue By Drug Class
5.2. Anti-vascular endothelial growth factor
5.2.1. Market Revenue and Growth Rate, 2015 ndash; 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 ndash; 2026 ($Million)
5.3. Others
5.3.1. Market Revenue and Growth Rate, 2015 ndash; 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 ndash; 2026 ($Million)

CHAPTER 6. Macular Degeneration Treatment MARKET BY END USERS

6.1. Global Macular Degeneration Treatment Revenue By End Users
6.2. Ambulatory Surgical Centers
6.2.1. Market Revenue and Growth Rate, 2015 ndash; 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 ndash; 2026 ($Million)
6.3. Hospitals
6.3.1. Market Revenue and Growth Rate, 2015 ndash; 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 ndash; 2026 ($Million)
6.4. Ophthalmic Clinics
6.4.1. Market Revenue and Growth Rate, 2015 ndash; 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 ndash; 2026 ($Million)

CHAPTER 7. NORTH AMERICA MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

7.1. North America Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 ndash; 2026 ($Million)
7.2. North America Macular Degeneration Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
7.3. U.S.
7.3.1. U.S. Macular Degeneration Treatment Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
7.3.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
7.3.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
7.4.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
7.4.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
7.5.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
7.5.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)

CHAPTER 8. EUROPE MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

8.1. Europe Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 ndash; 2026 ($Million)
8.2. Europe Macular Degeneration Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
8.3.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
8.3.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
8.4.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
8.4.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
8.5.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
8.5.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
8.6.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
8.6.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
8.7.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
8.7.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

9.1. Asia-Pacific Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 ndash; 2026 ($Million)
9.2. Asia-Pacific Macular Degeneration Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
9.3.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
9.3.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
9.4.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
9.4.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
9.5.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
9.5.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
9.6.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
9.6.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
9.7.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
9.7.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
9.8.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
9.8.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)

CHAPTER 10. LATIN AMERICA MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

10.1. Latin America Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 ndash; 2026 ($Million)
10.2. Latin America Macular Degeneration Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
10.3.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
10.3.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
10.4.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
10.4.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
10.5.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
10.5.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)

CHAPTER 11. MIDDLE EAST MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

11.1. Middle East Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 ndash; 2026 ($Million)
11.2. Middle East Macular Degeneration Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
11.3.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
11.3.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
11.4.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
11.4.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
11.5.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
11.5.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)

CHAPTER 12. AFRICA MACULAR DEGENERATION TREATMENT MARKET BY COUNTRY

12.1. Africa Macular Degeneration Treatment Market Revenue and Growth Rate, 2015 ndash; 2026 ($Million)
12.2. Africa Macular Degeneration Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
12.3.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
12.3.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
12.4.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
12.4.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Disease Indication, 2015 ndash; 2026 ($Million)
12.5.2. Market Revenue and Forecast By Drug Class, 2015 ndash; 2026 ($Million)
12.5.3. Market Revenue and Forecast By End Users, 2015 ndash; 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. GlaxoSmithKline plc
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Novartis AG
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Bayer AG
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Neurotech Pharmaceuticals, Inc.
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Ophthotech Corporation
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. F. Hoffmann-La Roche Ltd.
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. StemCells Inc.
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Pfizer, Inc.
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Sanofi
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Santen Pharmaceuticals
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Type Portfolio
13.10.5. Key Developments
13.10.6. Strategies
13.11. Allergan, Inc.
13.11.1. Company Snapshot
13.11.2. Overview
13.11.3. Financial Overview
13.11.4. Type Portfolio
13.11.5. Key Developments
13.11.6. Strategies
13.12. Valeant Pharmaceuticals
13.12.1. Company Snapshot
13.12.2. Overview
13.12.3. Financial Overview
13.12.4. Type Portfolio
13.12.5. Key Developments
13.12.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

To Purchase this Premium Report@https://www.acumenresearchandconsulting.com/buy-now/0/1203

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

Editor Details

Last Updated: 28-Mar-2019